StocksDeepDive
Snapshot · ASX Health Care · generated 2026-09-26 00:47 UTC

CGS.AX — Cogstate Limited

EXPENSIVE (MOS -83.2%) · Quality 76/100

Price
3.37
Intrinsic value
1.84
Margin of safety
-83.2%
Implied growth (reverse DCF)
+23.4%
model assumes +15.5%
Value Score
9.9
Quality
76
Psychology
-31.1
Discovery
12
price/volume attention only
Moat score
69.5
erosion: none

Value Score: bottom 10% of ASX Health Care · Quality: top 19%

Dividend: 0.04/share (TTM) · yield 1.2% · payout 44%

Open the interactive Deep Dive for CGS.AX →

Use this data programmatically

This page's numbers are also available as JSON at /api/v1/deep-dive/CGS.AX - see the API docs for the full read-only surface, including an MCP server for AI assistants.

Common questions

Is CGS.AX undervalued?

As of 2026-09-26, CGS.AX trades at 3.37 against a computed intrinsic value of 1.84 (-83.2% margin of safety) - StocksDeepDive's valuation label for this is EXPENSIVE. This is a described calculation from public data, not a recommendation.

What is Cogstate Limited's Value Score?

Cogstate Limited's Value Score is 9.9 as of 2026-09-26 - it combines value, quality, crowd psychology and market attention into one number.

Does CGS.AX pay a dividend?

Yes - CGS.AX's trailing twelve-month dividend is 0.04/share, a yield of 1.2% at the current price (as of 2026-09-26).